期刊文献+

他克莫司对肾小管上皮细胞转分化早期CTGF、VEGF表达的影响 被引量:2

Effects of Tacrolimus on transdifferentiation and CTGF,VEGF early expression of human renal tubular epithelial cells
下载PDF
导出
摘要 目的探讨不同剂量的他克莫司(FK506)对肾小管上皮细胞(HKC)转分化的作用及其对早期结缔组织生长因子(CTGF)、血管内皮生长因子(VEGF)表达的影响。方法以体外培养的HKC为研究对象,分4组:(1)对照组;(2)转化生长因子-β1(TGF-β1)(8ng/mL)组;(3)FK506(10、30、60ng/mL)组;(4)TGF-β1(8ng/mL)加FK506(10、30、60ng/mL)组。应用形态学、免疫组化技术、和半定量反转录PCR(RT-PCR)观察FK506对TGF-β1诱导的HKC转分化的作用及对α-SMA、CTGF、VEGF表达的影响。结果与对照组比较,48h后TGF-β1组HKC细胞呈现出长梭形外观,α-平滑肌肌动蛋白(α-SMA)、CTGF、VEGF的表达明显增多(P<0.01),FK506组α-SMA、VEGF及CTGF的表达差异无统计学意义(P>0.05)。TGF-β1加FK506组比TGF-β1组α-SMA、VEGF及CTGF随FK506的浓度增加表达明显降低(P<0.05)。结论 FK506对TGFβ1诱导的肾小管上皮细胞转分化早期可能通过下调VEGF、CTGF的表达起抑制作用。 Objective To explore different doses of tacrolimus(FK506) to renal tubular epithelial cells(HKC) transdifferentia tion and its early action on connective tissue growth factor(CTGF),vascular endothelialgrowth factor (VEGF) expressing change. Methods The human kidney cells(HKC) were cultured for 48 hours in different conditions: (1)Serum free as control, (2)Treated with TGF-β1(8 ng/mL) ;(3)Treated with FK506 at different concentration(10,30,60 ng/mL) ; (4)Treated with FK506 at different concentration(10,30,60 ng/mL) plus TGF-β1 (ng/mL). The expression of α-SMA was assessed with RT-PCR,The expression of CTGF,VEGF was assessed with RT-PCR and immunohistochemistry after 48 hours. Results Compared with the control group, The expression of CTGF, VEGF and α-SMA mRNA was markedly increased in HCK cultured with TGF-βI group(P〈0.05), which were suppressed significantly in HKC cultured with TGF-β1 plus FK506 group(P〈0.05). Conclusion The inhibition of FK506 on transdifferentiation of tubular epithelial ceils may be related to the down-regulation of VEGF,CTGF.
出处 《重庆医学》 CAS CSCD 北大核心 2012年第32期3401-3403,3407,F0003,共5页 Chongqing medicine
关键词 他克莫司 肾小管 细胞转分化 血管内皮生长因子类 结缔组织生长因子 tacrolimus kidney tubules cell transdifferentiation vascular endothelial growth factors connective tissue growthfactor
  • 相关文献

参考文献15

  • 1Nangaku M. Mechanisms of tubulointerstitial injury in the kidney: final common pathways to end-stage renal failure [J]. Int Med,2004,43(1) :9-7.
  • 2Liu YH. Epithelial to mesenchymal transition in renal fi- brogenesis., pathologic significance, molecular mecha- nism,and therapeutic intervention[J]. J Am Soc Nephrol, 2004,15(1):1-5.
  • 3Cox CM, D' Agostino SL, Miller MK, et al. Apelin, the ligand for the endothelial G-protein coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo [J]. Dev Biol, 2006,296(1) :177-189.
  • 4Schmierer B, Hill CS. TGF beta-SMADsignal transduction: molecular specificity and functional flexibility[J]. Nat Rev Mol Cell Biol, 2007,8 (12) : 970- 982.
  • 5Bot finger EP,Bitzer M. TGF2beta signaling in renal dis- ease[J]. J Am Soc Nephrol,2002,13(2) :2600-2610.
  • 6Phanish MK, Winn SK, Dockrell ME. Connective tissue growth factor-(CTGF, CCN2)-a marker, mediator and therapeutic target for renal fibrosis [J]. Nephron Exp Nephrol,2010,114(3) :83-92.
  • 7Chen XM, Qi W, Pollock CA,CTGF and chronic kidney fibrosis[M]. Front Biosci: Schol Ed, 2009 : 132-141.
  • 8Kang DH, Kanellis J, Hugo C,et al. Role of the microvas- cular endothelium in progressive renal disease [J]. J Am SocNephrol, 2002,13 (3) : 806-816.
  • 9Maharaj AS, Saint-Geniez M, Maldonado AE, et al. Vas- cular endothelial growth factor localization in the adult [J]. Am J Pathol,2006,168(2) :639-648.
  • 10Wang L, Kwak JH, Kim SI, et al. Transiorming growth factor-betal stimulates vascular endothelial growth factor 164 via3 -p38alpha mitogen-activated protein kinase andp38delta mitogen-activated protein kinase -dependent pathway in murine mesangial cells[J]. Biol Chem, 2004, 279(32) : 33213-33219.

二级参考文献15

  • 1Cox CM,D'Agostino SL,Miller MK,et al.Apelin,the ligand for the endothelial G-protein-coupled receptor,APJ,is a potent angiogenic factor required for normal vascular development of the frog embryo[J].Dev Biol,2006,296(1):177-189.
  • 2Acevedo LM,Londono I,Oubaha M,et al.Glomerular CD34 expression in short-and long-term diabetes[J].J Histochem Cytochem,2008,56(6):605-614.
  • 3Pareek G,Shevchuk M,Armenakas NA,et al.The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density:a possible mechanism for decreased prostatic bleeding in treated patients[J].J Urol,2003,169(1):20-23.
  • 4Jensen LJ,Denner L,Schrijvers BF,et al.Renal effects of a neutralising RAGE-antibody in long-term streptozotocin-diabetic mice[J].J Endocrinol,2006,188(3):493-501.
  • 5Bortoloso E,Del Prete D,Dalla Vestra1 M,et al.Quantitave and qualitative changes in vascular endothelial growth factor gene expression in glomeruli of patients with type 2 diabetes[J].Eur J Endocrinol,2004,150(6):799-807.
  • 6De Vriese AS,Tilton RG,Stephan CC,et al.Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane[J].J Am Soc Nephrol,2001,12(8):1734-1741.
  • 7Tsuchida K,Makita Z,Yamagishi S,et al.Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor,OPB-9195[J].Diabetologia,1999,42(5):579-588.
  • 8Cooper ME,Vranes D,Youssef S,et al.Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes[J].Diabetes,1999,48(11):2229-2239.
  • 9Chiarelli F,Spagnoli A,Basciani F,et al.Vascular endothelial growth factor (VEGF) in children,adolescents and young adults with type 1 diabetes mellitus:relation to glycaemic control and microvascular complications[J].Diabet Med,2000,17(9):650-656.
  • 10Cha DR,Kim NH,Yoon JW,et al.Role of vascular endothelial growth factor in diabetic nephropathy[J].Kidney Int,2000,77:S104-S112.

共引文献10

同被引文献26

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部